In a female patient with severe pulmonary hypertension, does the condition affect iron status or cause iron deficiency?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yes, Severe Pulmonary Hypertension Significantly Affects Iron Status

Iron deficiency is highly prevalent in patients with severe pulmonary hypertension, occurring in approximately 40-67% of PAH patients, and is associated with worse clinical outcomes including reduced exercise capacity and potentially higher mortality. 1, 2, 3

The Mechanism: Why PH Causes Iron Deficiency

The relationship between pulmonary hypertension and iron deficiency involves multiple pathophysiological mechanisms:

Impaired Gastrointestinal Iron Absorption: PAH patients demonstrate significantly reduced oral iron uptake compared to healthy controls—even those without chronic iron deficiency show similar absorption impairment as those with established deficiency 2. This suggests that factors beyond depleted iron stores, particularly chronic inflammation, impair intestinal iron absorption in this population.

Hepcidin Dysregulation: PAH patients show elevated hepcidin expression and reduced hepatic iron storage 4. Hepcidin blocks intestinal iron absorption and iron release from stores, creating a functional iron deficiency even when total body iron may be present.

Metabolic Consequences: Iron deficiency in PAH triggers a cascade through the HIF2α pathway, suppressing mitochondrial complex activity, increasing oxidative stress, and promoting metabolic reprogramming in pulmonary arterial endothelial cells—ultimately worsening pulmonary vascular remodeling and right ventricular function 4.

Clinical Implications

Exercise Capacity and Functional Status: Iron deficiency correlates with reduced 6-minute walk distance and worse WHO functional class, independent of anemia severity 5, 6.

Disease Severity: Iron deficiency is associated with worse hemodynamic parameters and may predict reduced exercise capacity, particularly when defined as transferrin saturation <20% 7.

Right Ventricular Function: Iron deficiency compromises right ventricular adaptation to increased afterload, contributing to heart failure progression 3, 6.

Diagnostic Approach

Screen all PAH patients for iron deficiency using:

  • Ferritin levels
  • Transferrin saturation (TSAT)
  • Consider soluble transferrin receptor in inflammatory states

Apply the ESC/ERS guideline definition 1:

  • Iron deficiency = ferritin <100 μg/L OR ferritin 100-300 μg/L with TSAT <20%

However, recognize that TSAT <20% alone may better identify patients with reduced exercise capacity 7, particularly when ferritin is elevated due to inflammation.

Treatment Considerations

Oral iron supplementation is often insufficient in PAH due to impaired gastrointestinal absorption mediated by hepcidin upregulation 1, 2. The ESC/ERS guidelines suggest that intravenous iron administration may be preferable 1.

Evidence for IV iron (ferric carboxymaltose) shows:

  • Sustained improvement in iron parameters for up to 18 months
  • Improved 6-minute walk distance (377.5m to 412.5m at 6 months)
  • Better WHO functional class
  • Reduced hospitalizations for worsening PAH
  • Good safety profile 5

The ESC/ERS guidelines state that "correction of anemia and/or iron status may be considered in PAH patients" (Class IIb, Level C) 1, though this is a weak recommendation reflecting limited controlled trial data.

Critical Caveats

Iron deficiency in PAH often occurs without anemia—only 19-31% of iron-deficient PAH patients have concurrent anemia 2, 7. Therefore, do not wait for anemia to develop before screening and treating iron deficiency.

Recurrent deficiency is common: approximately 24% of patients required a second IV iron infusion within 9-10 months 5, necessitating ongoing monitoring.

The optimal definition of iron deficiency in PAH remains debated: while guidelines use ferritin-based criteria, TSAT <20% may better identify functionally significant deficiency 7.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.